{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"6.800","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"111,468,814","primaryexch":"HKEX","ric":"2496.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"M","am_u":"K","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BNNMZ08","am":"72.53","iv":"","ew_strike":"","as":"6.980","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"5.320","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"200","update_time":"2025-09-26 10:38:37.0","lo52":"3.650","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Zhou Pengfei","underlying_ric":"2496.HK","hi52":"8.280","issuer_name":"Wuhan YZY Biopharma Co., Ltd. - B - H Shares","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 13:55","aum_date":"","lo":"6.300","mkt_cap":"757.98","f_aum_hkd":null,"ew_sub_per_to":"","ls":"6.800","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"+0.500","aum":"","issued_shares_class_B":null,"vo":"11.00","secondary_listing_flag":false,"listing_date":"25 Sep 2023","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Wuhan YZY Biopharma Co., Ltd. - B - H Shares","nm_s":"YZYBIO-B","sym":"2496","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Wuhan YZY Biopharma Co Ltd is a China-based company mainly engaged in the discovery, development, and commercialization of new innovative drugs in the field of anti-tumor bispecific antibodies. The Company is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The Company's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The Company's product pipeline also includes Y101D, Y332, Y225, and others.","op":"6.300","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"No. 666 Gaoxin Road<br/>East Lake High Tech<br/>Development Zone<br/>Wuhan, Hubei Province, PRC","pc":"+7.94","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"6.300","isin":"CNE1000063C4","moneyness":""}},"qid":"1758891010928"}
